优化转移性结直肠癌的第一线治疗方法
Sara Cherri1, Ester Oneda1, Laura Zanotti1
1Department of Clinical Oncology, Fondazione Poliambulanza, Brescia, Italy.
Frontiers in oncology
|November 1, 2023
概括
结肠直肠癌需要基于特定患者特征的个性化治疗策略. 未来的研究将专注于组合疗法,以克服治疗耐药性并改善患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
背景情况:
- 结肠直肠癌 (CRC) 由于其高发病率和复杂的生物学,构成了全球重大健康挑战.
- 目前的治疗方法往往产生不理想的结果,需要超越一种适合所有人的策略.
研究的目的:
- 强调基于独特的生物和临床特征对结直肠癌患者分层的重要性.
- 突出开发向治疗和组合治疗的必要性,以改善患者的治疗结果.
主要方法:
- 审查目前的临床实践和结直肠癌的新兴治疗目标.
- 分析患者的基本特征,包括瘤侧向,微卫星不稳定 (MSI) 状态和特定突变.
- 探索克服治疗耐药性的策略.
主要成果:
- 基于瘤侧向,MSI状态和分子标记物的CRC分层对于治疗效益至关重要.
- 预后和预测突变的识别指导对当前治疗的反应,并指向新的治疗点.
- 了解和规避阻力机制是改善长期结果的关键挑战.
结论:
- 考虑到个体瘤特征的个性化医疗方法对于优化结直肠癌治疗至关重要.
- 未来的努力应专注于开发具有有利毒性概况的有效组合疗法.
- 将有效的向治疗转移到一线设置和完善患者选择将提高可访问性和有效性.
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K